Navigation Links
Synthetech Reports First Quarter Fiscal 2010 Results
Date:8/6/2009

ALBANY, Ore., Aug. 6 /PRNewswire-FirstCall/ -- Synthetech, Inc. (OTC Bulletin Board: NZYM) today announced financial results for the first quarter of fiscal 2010, which ended June 30, 2009. Revenue for the quarter was $4.7 million, a 5% decrease compared to revenue of $4.9 million in the first quarter of fiscal 2009. Operating income for the current quarter was $1.0 million, compared to operating income of $314,000 for the same period last year. Net income for the current quarter was $969,000, or $0.07 per basic share, compared to last year's first quarter net income of $295,000, or $0.02 per share.

International sales, mainly to Europe, were $2.9 million and $2.6 million in the first quarters of fiscal 2010 and 2009, respectively. International sales, like all of Synthetech's revenues, are subject to significant quarterly fluctuations.

The improvement in fiscal 2010 first quarter net income on slightly lower sales is primarily the result of: a more favorable product mix; improved throughput and efficiencies; and raw material and other cost reductions. Additionally, gross income for the first quarter of fiscal 2009 was hindered by: lower than normal margins on certain products which encountered production difficulties in prior quarters; higher than average raw material costs on certain projects; and low margins on material purchased for direct resell. The first quarter of fiscal 2010 includes $224,000 of employee incentives compared to $41,000 in the comparable period of fiscal 2009. As a cautionary measure, in May 2009, Synthetech implemented a reduction in force and modified its shift schedules to reduce the cost of overtime pay. As a result of these changes, Synthetech incurred $53,000 of severance costs in the first quarter of fiscal 2010.

Synthetech's cash and cash equivalents were $3.1 million at June 30, 2009, compared to $588,000 at March 31, 2009. Synthetech'
'/>"/>

SOURCE Synthetech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Synthetech Earns National Recognition for Performance Improvement Program
2. Synthetech Announces Fiscal 2008 Results
3. Synthetech Announces New Director of Manufacturing
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Japan , April 16, 2015  Center ... University and Takeda Pharmaceutical Company Limited (Takeda) announced ... clinical applications of induced pluripotent stem cells in ... disorders and cancer immunotherapy. The "Takeda-CiRA Joint Program ... expedite multiple research projects for drug discovery and ...
(Date:4/16/2015)... Proove Biosciences , Inc. is pleased to ... for the 2015 BIO International Convention. Hosted by the ... will take place June 15-18 at the Pennsylvania Convention ... contest, industry leaders will be voting for companies they ... community voting period began on April 14, 2015 and ...
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... a Tool to Make Soyfoods Even HealthierST. LOUIS, March ... healthcare professionals believe soy to be beneficial to the ... method to make food products such as soyfoods even ... Biotechnology Awareness & Attitude Survey - sponsored by ...
... cell line manufacturing, Selexis is now offering a ... drugs with added characterization servicesGENEVA, March 31 ... and services for the rapid development of high-performance ... offering focusing on the biosimilar market segment. ...
... March 31 Sigma-Aldrich (Nasdaq: ... quality services and oligonucleotides to Gene Oracle, an innovative ... agreement, Sigma-Aldrich will be the exclusive supplier of custom ... engage in co-marketing efforts to promote the GeneIOS system ...
Cached Biology Technology:Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 3Selexis Launches Biosimilar Cell Line Development Program 2Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 2Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 3
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... study of more than 68,000 infants published in this ... Rotateq demonstrated that it can safely prevent 98 percent ... account for 2 million hospital visits and 500,000 pediatric ... largest pre-licensure vaccine clinical trials ever conducted worldwide, research ...
... against the Epstein-Barr virus, the virus that most often ... sclerosis 15 to 20 years later, according to a ... June 2006 print issue of Archives of Neurology, one ... that external factors may influence the risk for multiple ...
... called statins do not appear to reduce the incidence ... of previous studies in the January 4 issue of ... the risk of developing cancer, the authors provide as ... been studied in numerous large-scale, randomized, active- or placebo-controlled ...
Cached Biology News:New vaccine for condition that kills 500,000 children a year 2New vaccine for condition that kills 500,000 children a year 3Epstein-Barr virus may be associated with multiple sclerosis 2Statins have neutral effect on risk of cancer 2
Mouse Anti-Lamin B...
Hybridization Buffer 3.6 ml...
Chicken polyclonal to Thaumatin 2 ( Abpromise for all tested applications). Antigen: Full length Thaumatin 2...
Proteinase K Buffer 3.9 ml...
Biology Products: